# Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.

> **NCT03388853** · PHASE4 · COMPLETED · sponsor: **Neutec Ar-Ge San ve Tic A.Ş** · enrollment: 68 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Acetylcysteine/Doxofylline
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03388853
- **Lead sponsor:** Neutec Ar-Ge San ve Tic A.Ş
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-20
- **Primary completion:** 2019-12-21
- **Final completion:** 2019-12-21
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03388853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03388853, "Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03388853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*